Ming-Yan Wang

Ming-Yan Wang

Auto-generated profile, based on publicly available information

Ming-Yan Wang

Department of Medical College Jiangsu University Zhenjiang China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2021 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
FJfeng jiang
feng jiang
XWXin-Yu Wang
Xin-Yu Wang
MWMing-Yan Wang
Ming-Yan Wang
YMYan Mao
Yan Mao
XMXiao-Lin Miao
Xiao-Lin Miao
GZGuoping Zhou
Guoping Zhou
Objective. The aim of this research was to create a new genetic signature of immune checkpoint-associated genes as a prognostic method for pediatric acute myeloid leukemia (AML). Methods. Transcriptome profiles and clinical follow-up details were obtained in Therapeutically Applicable Research to Generate Effective Treatments (TARGET), a database of pediatric tumors. Secondary data was collected from the Gene Expression Omnibus (GEO) to test the observations. In univariate Cox regression and multivariate Cox regression studies, the expression of immune checkpoint-related genes was studied. A three-mRNA signature was developed for predicting pediatric AML patient survival. Furthermore, the GEO cohort was used to confirm the reliability. A bioinformatics method was utilized to identify the diagnostic and prognostic value. Results. A three-gene (STAT1, BATF, EML4) signature was developed to identify patients into two danger categories depending on their OS. A multivariate regression study showed that the immune checkpoint-related signature (STAT1, BATF, EML4) was an independent indicator of pediatric AML. By immune cell subtypes analyses, the signature was correlated with multiple subtypes of immune cells. Conclusion. In summary, our three-gene signature can be a useful tool to predict the OS in AML patients.

28 August 2026 in Med Research
Verified
Journal Article
Open access
PDF file
ZYZhang Yue
Zhang Yue
YFYi‐Cheng Fu
Yi‐Cheng Fu
WZWen Zuo
Wen Zuo
LWLi‐Na Wang
Li‐Na Wang
XSXing‐Xing Suo
Xing‐Xing Suo
MWMing‐Yan Wang
Ming‐Yan Wang
Chronic respiratory diseases (CRDs) remain a major source of mortality and disability worldwide, yet current evidence on their long‐term burden in the WHO Western Pacific Region (WPR) is limited. This study assessed temporal trends, demographic disparities, subtype composition, and major modifiable risk factors for CRDs from 1990 to 2023 in the WPR membership fixed at the study endpoint (WPR‐37). Estimates were extracted from the IHME GBD 2023 results tool for the aggregate location “Western Pacific Region” (location ID 44568), comprising 37 WHO Member States and areas as of 31 December 2023; Indonesia was excluded. We analyzed incidence, prevalence, deaths, and disability‐adjusted life years (DALYs), reporting absolute numbers and age‐standardized rates (ASRs). Trends were quantified using estimated annual percentage change (EAPC). Attributable deaths and DALYs were assessed for tobacco smoking, air pollution, and occupational exposure. In 2023, CRDs in WPR‐37 accounted for 22.0 million incident cases, 155.9 million prevalent cases, 1.4 million deaths, and 29.9 million DALYs. Compared with 1990, absolute numbers increased across all indicators, whereas ASRs were stable or declined. Age‐standardized incidence and prevalence rates decreased modestly, whereas age‐standardized mortality and DALY rates declined more markedly, with EAPCs of −2.67% (95% confidence interval [CI]: −3.02 to −2.33) and −2.31% (95% CI: −2.56 to −2.05), respectively. The burden increased sharply with age, remained higher in males, and was dominated by chronic obstructive pulmonary disease, accounting for 75.3% of DALYs. Tobacco smoking and air pollution were the leading selected modifiable contributors, whereas six‐country comparisons showed marked regional heterogeneity. Although age‐standardized mortality and DALY rates declined substantially, the absolute burden continued to rise, mainly reflecting population growth and aging. The burden remained concentrated in older adults, males, and chronic obstructive pulmonary disease. These estimates describe WPR‐37 rather than the current 38‐member WPR.